Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

PURPOSE: The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective MET inhibitor) plus gefitinib versus chemotherapy in patients with MET-altered EGFR-mutant NSCLC (data cut-off: September 3, 2021). PATIENTS AND METHODS: Adults with advanced/metastatic EGFR-mutant NSCLC, acq...

Descripción completa

Detalles Bibliográficos
Autores principales: Liam, Chong Kin, Ahmad, Azura Rozila, Hsia, Te-Chun, Zhou, Jianying, Kim, Dong-Wan, Soo, Ross Andrew, Cheng, Ying, Lu, Shun, Shin, Sang Won, Yang, James Chih-Hsin, Zhang, Yiping, Zhao, Jun, Berghoff, Karin, Bruns, Rolf, Johne, Andreas, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183805/
https://www.ncbi.nlm.nih.gov/pubmed/36971777
http://dx.doi.org/10.1158/1078-0432.CCR-22-3318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183805/
https://www.ncbi.nlm.nih.gov/pubmed/36971777
http://dx.doi.org/10.1158/1078-0432.CCR-22-3318

Ejemplares similares